ATE20250T1 - Herstellung von hepatitis-a-virus mit hohem titer. - Google Patents

Herstellung von hepatitis-a-virus mit hohem titer.

Info

Publication number
ATE20250T1
ATE20250T1 AT81401172T AT81401172T ATE20250T1 AT E20250 T1 ATE20250 T1 AT E20250T1 AT 81401172 T AT81401172 T AT 81401172T AT 81401172 T AT81401172 T AT 81401172T AT E20250 T1 ATE20250 T1 AT E20250T1
Authority
AT
Austria
Prior art keywords
hepatitis
virus
production
high title
title
Prior art date
Application number
AT81401172T
Other languages
German (de)
English (en)
Inventor
Henry Z Markus
William J Mcaleer
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE20250T1 publication Critical patent/ATE20250T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32451—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT81401172T 1980-07-23 1981-07-22 Herstellung von hepatitis-a-virus mit hohem titer. ATE20250T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/171,621 US4301249A (en) 1980-07-23 1980-07-23 High titer production of hepatitis A virus
EP81401172A EP0044793B1 (en) 1980-07-23 1981-07-22 High titer production of hepatitis a virus

Publications (1)

Publication Number Publication Date
ATE20250T1 true ATE20250T1 (de) 1986-06-15

Family

ID=22624494

Family Applications (1)

Application Number Title Priority Date Filing Date
AT81401172T ATE20250T1 (de) 1980-07-23 1981-07-22 Herstellung von hepatitis-a-virus mit hohem titer.

Country Status (11)

Country Link
US (1) US4301249A (cg-RX-API-DMAC7.html)
EP (1) EP0044793B1 (cg-RX-API-DMAC7.html)
JP (1) JPS5753410A (cg-RX-API-DMAC7.html)
AT (1) ATE20250T1 (cg-RX-API-DMAC7.html)
CA (1) CA1187413A (cg-RX-API-DMAC7.html)
DE (1) DE3174765D1 (cg-RX-API-DMAC7.html)
DK (1) DK326781A (cg-RX-API-DMAC7.html)
ES (1) ES504199A0 (cg-RX-API-DMAC7.html)
GR (1) GR74594B (cg-RX-API-DMAC7.html)
IE (1) IE51454B1 (cg-RX-API-DMAC7.html)
PT (1) PT73371B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783407A (en) * 1985-09-30 1988-11-08 Merck & Co., Inc. Growth of hepatitus A virus in vero cells
DE3633550A1 (de) * 1986-10-02 1988-04-14 Behringwerke Ag Vaccine gegen hepatitis a
US5268292A (en) * 1988-06-27 1993-12-07 Robertson Betty H Reproducible generation of high yields of hepatitis A virus by cell culture
AU650711B2 (en) * 1990-12-13 1994-06-30 Cellco, Inc. Sustained and continuous production of high titers of recombinant viral vectors and transduced target cells for use in gene therapy
US5506129A (en) * 1991-05-24 1996-04-09 Evans Medical Limited Virus production
DZ1706A1 (fr) * 1992-08-07 2002-02-17 Merck & Co Inc Vaccin contre le virus de l'hepatite a.
US5354692A (en) * 1992-09-08 1994-10-11 Pacific Biotech, Inc. Analyte detection device including a hydrophobic barrier for improved fluid flow
HRP950097A2 (en) * 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
US5498537A (en) * 1994-03-09 1996-03-12 Cellco, Inc. Serum-free production of packaged viral vector
US20020182730A1 (en) * 1995-07-26 2002-12-05 Micheal L. Gruenberg Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
FR2821947B1 (fr) * 2001-03-12 2003-05-16 Canon Kk Procede et dispositif de validation de parametres definissant une image
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
US20030134341A1 (en) * 2001-09-19 2003-07-17 Medcell Biologics, Llc. Th1 cell adoptive immunotherapy
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
EP1497444B1 (en) * 2002-03-27 2015-11-04 Immunex Corporation Methods for increasing polypeptide production
US20100028973A1 (en) * 2006-09-26 2010-02-04 Kyoto University Method for proliferating hepatitis virus, hollow fiber for culturing hepatitis virus-infected cells, and use thereof
MX2009011899A (es) * 2007-05-04 2010-03-30 Baxter Int Perfil de temperatura de dos pasos para la propagacion de virus.
JP5692688B2 (ja) * 2008-06-26 2015-04-01 東洋紡株式会社 感染性ｃ型肝炎ウイルス粒子の製造方法、およびその利用
WO2012122625A1 (en) 2011-03-14 2012-09-20 National Research Council Of Canada Method of viral production in cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3615024A (en) * 1968-08-26 1971-10-26 Amicon Corp High flow membrane
US3821087A (en) * 1972-05-18 1974-06-28 Dedrick R Cell culture on semi-permeable tubular membranes
US3883393A (en) * 1972-05-18 1975-05-13 Us Health Education & Welfare Cell culture on semi-permeable tubular membranes
US3997396A (en) * 1973-07-02 1976-12-14 Monsanto Company Method for the in vitro propagation and maintenance of cells
US4087327A (en) * 1976-04-12 1978-05-02 Monsanto Company Mammalion cell culture process
FR2398504A1 (fr) 1977-07-29 1979-02-23 Tours Inst Virologie Culture de virus de l'hepatite a, in vitro. application a la production d'un antigene reactif, d'immunserums specifiques et de vaccins contre l'hepatite a
US4164566A (en) * 1978-08-17 1979-08-14 Merck & Co., Inc. Hepatitis a virus cell culture in vitro
US4301250A (en) * 1979-11-02 1981-11-17 Merck & Co., Inc. Method of producing hepatitis B surface antigen

Also Published As

Publication number Publication date
JPS5753410A (en) 1982-03-30
CA1187413A (en) 1985-05-21
DK326781A (da) 1982-01-24
GR74594B (cg-RX-API-DMAC7.html) 1984-06-29
EP0044793A2 (en) 1982-01-27
IE51454B1 (en) 1986-12-24
PT73371A (en) 1981-08-01
ES8205016A1 (es) 1982-05-16
PT73371B (en) 1983-06-15
US4301249A (en) 1981-11-17
IE811655L (en) 1982-01-23
DE3174765D1 (en) 1986-07-10
EP0044793B1 (en) 1986-06-04
ES504199A0 (es) 1982-05-16
EP0044793A3 (en) 1983-01-05

Similar Documents

Publication Publication Date Title
ATE20250T1 (de) Herstellung von hepatitis-a-virus mit hohem titer.
DE3881971D1 (de) Erzeugung von mitteldestillation mit silicoaluminophosphat-molekularsieben.
DE3789399D1 (de) Herstellung von Vakkzinen gegen Hepatitis B-Virus.
ATE6402T1 (de) Verfahren zur herstellung von hepatitis b oberflaechenantigen.
ATE112802T1 (de) Herstellung von funktionellen menschlichen urokinasepolypeptiden.
IT1126375B (it) Metodo di fabbricazione di preforme di fibre ottiche
DK437988A (da) Fremgangsmaade til rensning af hepatitis a vironer
DE3582869D1 (de) Photoaetzverfahren zur herstellung von chirurgischen naehnadeln.
BG28411A4 (en) Method of obtaining of optical active compounds norpinene
SE7602751L (sv) Framstellning av n-acyl-l-metionin
DE3785132D1 (de) Herstellung optisch aktiver cyclopropancarbonsaeuren.
DK372780A (da) Fremgangsmaade til propagering af humant hepatitis a virus
DE3783675D1 (de) Verfahren zur herstellung von acrylfasern mit hohen fasereigenschaften.
ATE10806T1 (de) Verfahren zur herstellung von hepatitis boberfl[chenantigen.
ATE127526T1 (de) Verfahren zur herstellung von natürlichem hiv- glykoprotein 160.
DE3781749D1 (de) Herstellungsverfahren von optisch aktiven alkoholen.
ES2028968T3 (es) Sistema de gobierno de la produccion.
DE3863732D1 (de) Herstellung von vorformen fuer optische fasern.
ATE73792T1 (de) Annaeherung zur herstellung von natuerlicher vitamin e verwendender asymetrischer synthese.
DE3680706D1 (de) Vakuumspinnen von faserbuendeln.
DK0555333T3 (da) Kunstige virushylstre
BG28059A3 (en) Method of stereoselective obtaining of optical active transhexahydrobenzopyranones
DK0403015T3 (da) Fremgangsmåde til dyrkning af celler
DE68922778D1 (de) Erzeugung von Fehlernachrichtenanzeige.
SU1692147A1 (ru) Штамм гибридных культивируемых клеток животных mus musculus l. - продуцент моноклональных антител к 146 s-компоненту вируса ящура cn 564

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time